Tonix Pharmaceuticals (TNXP) Competitors $22.54 +0.05 (+0.22%) Closing price 04:00 PM EasternExtended Trading$22.70 +0.16 (+0.69%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. PHAT, ABUS, PROK, XNCR, IOVA, MRVI, RZLT, DAWN, KURA, and AVXLShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Phathom Pharmaceuticals (PHAT), Arbutus Biopharma (ABUS), ProKidney (PROK), Xencor (XNCR), Iovance Biotherapeutics (IOVA), Maravai LifeSciences (MRVI), Rezolute (RZLT), Day One Biopharmaceuticals (DAWN), Kura Oncology (KURA), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Its Competitors Phathom Pharmaceuticals Arbutus Biopharma ProKidney Xencor Iovance Biotherapeutics Maravai LifeSciences Rezolute Day One Biopharmaceuticals Kura Oncology Anavex Life Sciences Phathom Pharmaceuticals (NASDAQ:PHAT) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation. Do insiders and institutionals have more ownership in PHAT or TNXP? 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is PHAT or TNXP more profitable? Phathom Pharmaceuticals has a net margin of -289.51% compared to Tonix Pharmaceuticals' net margin of -828.22%. Phathom Pharmaceuticals' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-289.51% N/A -90.40% Tonix Pharmaceuticals -828.22%-57.93%-51.04% Do analysts recommend PHAT or TNXP? Phathom Pharmaceuticals currently has a consensus price target of $17.50, indicating a potential upside of 50.34%. Tonix Pharmaceuticals has a consensus price target of $70.00, indicating a potential upside of 210.56%. Given Tonix Pharmaceuticals' higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has better valuation and earnings, PHAT or TNXP? Tonix Pharmaceuticals has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$55.25M14.95-$334.33M-$4.73-2.46Tonix Pharmaceuticals$9.83M20.10-$130.04M-$39.47-0.57 Which has more risk & volatility, PHAT or TNXP? Phathom Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Does the media prefer PHAT or TNXP? In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 6 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 0.44 beat Tonix Pharmaceuticals' score of -0.14 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryPhathom Pharmaceuticals beats Tonix Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$197.59M$2.64B$9.05B$10.60BDividend YieldN/A56.71%5.69%4.71%P/E Ratio-0.5723.7585.8427.34Price / Sales20.10578.86535.76202.47Price / CashN/A173.2337.9261.55Price / Book0.715.6413.056.78Net Income-$130.04M$32.78M$3.30B$275.79M7 Day Performance-8.82%6.32%4.81%2.64%1 Month Performance-12.70%13.80%9.99%9.14%1 Year Performance55.13%2.76%85.26%35.89% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals2.8081 of 5 stars$22.54+0.2%$70.00+210.6%+60.0%$197.59M$9.83M-0.5750Analyst ForecastPHATPhathom Pharmaceuticals2.4276 of 5 stars$12.10+2.4%$17.50+44.6%-32.9%$856.25M$55.25M-2.55110Analyst ForecastGap UpABUSArbutus Biopharma1.4814 of 5 stars$4.46-0.8%$5.00+12.2%+10.9%$855.94M$6.17M-15.4090News CoverageAnalyst ForecastPROKProKidney2.6907 of 5 stars$2.87+3.2%$6.25+117.8%+88.4%$847.83M$527K-5.053News CoverageAnalyst ForecastGap UpXNCRXencor3.7945 of 5 stars$11.90+0.7%$22.25+87.0%-36.2%$844.36M$110.49M-4.93280Analyst ForecastAnalyst RevisionGap UpIOVAIovance Biotherapeutics4.5409 of 5 stars$2.30+2.0%$11.90+418.5%-76.6%$834.06M$164.07M-1.87500News CoverageAnalyst ForecastMRVIMaravai LifeSciences3.359 of 5 stars$3.26+9.6%$5.22+60.3%-56.6%$828.64M$259.18M-2.39610Positive NewsRZLTRezolute2.6633 of 5 stars$9.11-0.9%$14.50+59.2%+82.4%$825.92MN/A-9.3840Analyst ForecastGap UpDAWNDay One Biopharmaceuticals3.0384 of 5 stars$8.03+8.0%$25.29+215.1%-44.8%$822.62M$131.16M-8.4560News CoveragePositive NewsAnalyst ForecastKURAKura Oncology4.0513 of 5 stars$9.32+2.0%$24.10+158.5%-44.5%$811.49M$53.88M-4.14130Analyst DowngradeAVXLAnavex Life Sciences3.7495 of 5 stars$9.41+3.1%$44.00+367.6%+88.0%$810.37MN/A-16.5540Analyst Forecast Related Companies and Tools Related Companies Phathom Pharmaceuticals Alternatives Arbutus Biopharma Alternatives ProKidney Alternatives Xencor Alternatives Iovance Biotherapeutics Alternatives Maravai LifeSciences Alternatives Rezolute Alternatives Day One Biopharmaceuticals Alternatives Kura Oncology Alternatives Anavex Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
